ApTOLL is under clinical development by AptaTargets and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase II drugs for Acute Ischemic Stroke have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ApTOLL’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ApTOLL overview

ApTOLL (ApTLR-4FT) is under development for the treatment of acute ischemic stroke, Intracerebral hemorrhage, myocardial infarction, multiple sclerosis, inflammation and coronavirus disease 2019 (COVID-19). It is administered as an intravenous infusion. The drug candidate is an aptamer which acts by targeting TLR-4 (Toll-Like receptor-4).

AptaTargets overview

AptaTargets is a biopharmaceutical company that develops therapeutic applications based on aptamer technology. The company’s products are used for the treatment of acute stroke, hemorrhage, acute myocardial infarction, multiple sclerosis, among others. Apta Targets carters in neuroprotection and immune modulation. Its aptamers are chemically synthesized alternatives of antibodies and feature highly reproducibility, stability at room temperature, and low immunogenicity. The company is a developing in aptatargets, aptoll and targeting indications. AptaTargets is headquartered in Madrid city, Madrid, Spain.

For a complete picture of ApTOLL’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.